Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Metrics to compare | ACON | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACONPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −1.0x | −0.6x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price / Book | 0.9x | 0.8x | 2.6x | |
Price / LTM Sales | 28.8x | 2.7x | 3.2x | |
Upside (Analyst Target) | 627.6% | 71.6% | 40.8% | |
Fair Value Upside | Unlock | 23.4% | 5.9% | Unlock |